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Abstract We have previously demonstrated that fibroblast
growth factor receptor 2 (FGFR2) activates ribosomal s6 ki-
nase 2 (RSK2) in mammary epithelial cells and that this path-
way promotes in vitro cell growth and migration. Potential
clinical significance of FGFR2 and RSK2 association has
never been investigated. Herein, we have undertaken an eval-
uation of a possible relationship between FGFR2/RSK2 inter-
dependence and disease outcome in breast cancer (BCa) pa-
tients. The clinical analysis was complemented by an in vitro
investigation of an involvement of RSK2 in the regulation of
FGFR2 function. Primary tumour samples from 152 stage I–
III BCa patients were examined for FGFR2 and RSK2 gene
and protein expression. FGFR2 showed a positive correlation
with RSK2 at both protein (p = 0.003) and messenger RNA
(mRNA) (p = 0.001) levels. Lack of both FGFR2 and activat-
ed RSK (RSK-P) significantly correlated with better disease-
free survival (DFS) (p = 0.01). Patients with tumours
displaying immunoreactivity for either or both FGFR2 and
RSK-P had 4.89-fold higher risk of recurrence when com-
pared to the FGFR2/RSK-P-negative subgroup. FGFR2-
RSK2 interactions were verified by co-immunoprecipitation
and internalization assays in HB2 mammary epithelial cell
line (characterized by high endogenous FGFR2 and RSK2
expression). In vitro analyses revealed that FGFR2 and
RSK2 formed an indirect complex and that activated RSK
exerted a significant impact on fibroblast growth factor 2
(FGF2)-triggered internalization of FGFR2. Our results sug-
gest that the FGFR2-RSK2 signalling pathway is involved in
pathophysiology of BCa and evaluation of FGFR2/RSK-P
expression may be useful in disease prognostication.
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Background
Fibroblast growth factor receptors (FGFRs) and their ligands
(FGFs) play an important role in mammalian ontogenesis,
angiogenesis and wound healing. FGFR family consists of
four tyrosine kinase receptors (FGFR1–4) that are expressed
in multiple alternatively spliced variants, which define ligand
specificity and downstream signalling pathways [1]. FGFR2
has been implicated in development and progression of breast
cancer (BCa). Genome-wide analysis has identified single nu-
cleotide polymorphisms (SNPs) in intron 2 of the FGFR2
gene associated with a higher risk of BCa [2]. In BCa patients,
increased both nuclear and cytoplasmic FGFR2 expression
correlated with lower overall and disease-free survival [3].
FGFR2 gene amplification was reported in approximately
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1–2 % of all breast cancers [4] and in about 4 % of triple-
negative tumours (TNBC) [5]. Preclinical studies of FGFR-
specific small molecule inhibitors provide evidence to suggest
that FGFR2 amplification might serve as a new therapeutic
target, especially in TNBC, notoriously resistant to currently
available therapies [5]. In accordance with that, a number of
experimental studies in various BCa models demonstrated
high efficiency of FGFR inhibitors in the induction of tumour
growth arrest [6–8]. In addition, FGFR2 was shown to con-
tribute to the maintenance of tumour-initiating cells (TICs), a
subpopulation with increased tumourigenic potential, self-re-
newal, heterogeneous differentiation and bipotency. TICs iso-
lated from human and mice mammary tumours were found to
be enrichedwith FGFR2-overexpressing population [9]. It has
also been reported that activation of FGFR2 enhanced inva-
sive growth of human BCa cells in mice [10], thus implicating
FGFR2 in both initiation and progression of the disease.
Ribosomal S6 kinase 2 (RSK2) is a member of the serine/
threonine kinase family consisting of four isoforms (RSK1–4)
in humans. Altered RSK signalling was found to support cell
transformation and tumour growth. Overexpression of RSK2
has been associated with several types of hematologic and
epithelial malignancies including breast cancer [11, 12].
Expression of RSK2 was elevated in about 50 % of mammary
tumours [13]. In BCa patients, RSK2 gene expression corre-
lated with poor disease-free survival [14]. Additionally, it was
demonstrated that specific inhibitors and small interfering
RNA (siRNA) targeting RSK2 significantly suppressed
growth and ability to self-renewal of TIC population within
TNBC and delayed tumour initiation in mice [14]. RSK2 was
also found to mediate the pro-migratory functions of ERK/
MEK pathway. A genome-wide messenger RNA (mRNA)
expression analysis revealed that MEK/ERK➔RSK signal-
ling regulates expression of 53 genes from diverse pathways
crucial for mammary cell motility and invasiveness [15].
In canonical pathway, RSK kinases are activated by
MAPK/ERK signalling in response to several growth factors,
peptide hormones and neurotransmitters, e.g. epidermal
growth factor (EGF), insulin and IGF-1 [16–18]. Alternative
mechanisms of RSK activation, including those mediated by
tyrosine kinase receptors, are being currently investigated. We
recently identified a new signalling pathway where fibroblast
growth factor 2 (FGF2)/FGFR2 indirectly activated RSK2 at
Tyr529 by p38 kinase in normal mammary and BCa cell lines.
This pathway was shown to co-exist with the classical MEK/
ERK-driven activation of RSK2. In addition, we demonstrat-
ed that RSK2was involved in FGF2/FGFR2-driven formation
of focal adhesions, cell migration and anchorage-independent
growth of BCa cells [19]. A number of other reports have
shown various interrelations between members of FGFR and
RSK families. For instance, FGFR3 has been proved to direct-
ly phosphorylate RSK2, which is known to play a critical role
in haematopoietic transformation [20]. The association
between the FGFR2 and RSK1 was shown to be involved in
FGFR2-induced AKT activation in epithelial cells [21]. On
the other hand, RSK2 appears to directly phosphorylate and
regulate endocytosis of FGFR1 in osteosarcoma cells.
Interaction between FGFR1 and RSK2 has been demonstrated
in yeast two-hybrid system and cell cultures [22]. Existing
knowledge of FGFR/RSK interdependence is almost exclu-
sively based on in vitro studies in various cellular models;
however, it is becoming increasingly evident that this associ-
ation might have important functional implications. The main
objective of this study was, therefore, to examine a possible
clinical significance of FGFR2/RSK2 interdependence at the
gene and protein levels in BCa patients, as well as to reveal
molecular basis of an involvement of RSK2 in the regulation
of FGFR2 function in mammary epithelial cells.
Both clinical material analyses and in vitro experiments
confirmed the postulated FGFR2/RSK2 interdependence. In
primary tumour samples of BCa, we found a positive, statis-
tically significant correlation between FGFR2 and RSK2 ex-
pression at both mRNA and protein levels. Importantly, phos-
phorylated RSK (RSK-P) as well as combined expression of
either or both FGFR2 and RSK-P was associated with poor
disease-free survival. RSK2 and FGFR2 were shown to form
a transient, indirect complex in mammary epithelial cells
in vitro. RSK activity was also identified to regulate FGFR2
internalization in response to ligand (FGF2) binding. Taken
together, our results indicate that FGFR2/RSK2 signalling
loop may participate in BCa progression and be predictive
of poor outcome in patients with breast carcinoma.
Materials and methods
Patient selection and samples
The study group included 152 patients with invasive breast
cancer (characteristics of the cohort are summarized in
Table 1) treated between 1999 and 2009 at the Medical
University Hospital in Gdansk. Primary tumour samples were
obtained by surgical excision or excisional biopsy prior to any
systemic treatment. Median age of the patients was 57 years
(range 27–86 years, average 58 years). Follow-up data were
available for 147 patients; median follow-up time was
50.5 months (range 1.6–103.5 months). Thirty-two patients
(21.05 %) developed tumour recurrence, and 23 (15.13 %)
died of BCa. Oestrogen receptor (ER) and progesterone recep-
tor (PgR) were scored according to the classical Allred system
with cut-point 3 for the positive result. Human epidermal
growth factor receptor 2 (HER2) status was assessed accord-
ing to the HercepTest criteria (Dako), with 3+ score defining
positive result. Scores (2+) were tested by FISH for HER2
gene amplification with the PathVysion® HER-DNA probe
kit (Abbott Molecular), as recommended by the manufacturer.
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RNA extraction and reverse transcription
After collection, tissue samples were immediately frozen in
liquid nitrogen and stored at −80 °C for further analyses.
Twenty to thirty milligrams of tissue was homogenized with
zircon beads in MagNA Lyser (Roche) for 40 s. Total RNA
was isolated by using RNeasy Mini Kit (Qiagen) according to
the manufacturer’s protocol, including on-column DNase I
treatment. For all samples, RNA concentration and purity
was determined by using the Nano-Drop ND-1000 spectro-
photometer (Thermo Scientific, USA). Qualitative analysis of
RNA was performed by microcapillary electrophoresis by
using the Agilent 2100 Bioanalyser (Expert software version
B.02.08) with an RNA 6000 Nano Kit (Agi lent
Technologies). For each sample, 1 μg of RNAwas used as a
template in reverse transcription (RT) reaction performed with
Transcriptor First Strand cDNA Synthesis Kit (Roche) in a
20 μl volume with random hexamer primers, according to
the manufacturer’s protocol.
qPCR and gene expression analysis
Gene expression level was determined by RT-qPCR in a
CFX96 thermal cycler (Bio-Rad). Reaction parameters were
as follows: 2 min at 50 °C, 10min at 95 °C, 40 cycles of 15 s at
95 °C followed by 1 min at 60 °C. Forty nanograms of cDNA
in 4 μl was added per reaction and mixed with 10 μl of
TaqMan Universal PCR Master Mix (Applied Biosystems,
Roche), 5 μl of water and 1 μl of specific primer and probe
mix. TaqMan Gene Expression Assays were used to measure
express ion of FGFR2 (Hs01552926_m1) , RSK2
(Hs00177936_m1) and two reference genes: GAPDH
(Hs99999905_m1) and ACTB (Hs99999903_m1). For each
gene tested, a control without RT reaction was included.
Samples were analysed in duplicates, and the average Cq value
used as a quantitative value. Relative expression values of each
gene were calculated by the delta-delta-Cq method normalized
to the reference genes and normal female human mammary
tissue (540045, Agilent Technologies) as a calibrator with the
use of qBasePLUS software (Biogazelle, ver. 2.0). Median
value of gene expression was a cut-off value for positivity.
Immunohistochemistry on tissue microarrays
TMAs were prepared as described before [23]. Serial 5-μm
paraffin sections of formalin-fixed blocks were processed for
immunohistochemistry for FGFR2 (mouse anti-human;
1:600; Abnova #H00002263-M01), RSK2 (rabbit anti-
human; 1:200; Life Span BioSciences, #LS-B7708) and
RSK-P (rabbit anti-human; 1:100, Sigma-Aldrich
#SAB4503961) by using protocols recommended by the man-
ufacturers. As a negative control for the immunostaining, pri-
mary antibodies were replaced by non-immune sera. Scoring
of immunostaining (no distinction was made between subcel-
lular distributions) was carried out as follows: (i) 0/negative—
no reactivity or only faint reactivity in <10 % of tumour cells,
(ii) 1+/negative—faint reactivity in ≥10 % of tumour cells,
(iii) 2+/positive—weak to moderate reactivity in ≥10 % of
Table 1 Patient characteristics
Patient characteristics (N = 152)
Age 27–86 (average 58)
N %
T stage
T1 53 34.87 %
T2 78 51.32 %
T3 9 5.92 %
T4 11 7.24 %
Missing data 1 0.66 %
N stage
N0 68 44.74 %
N1 50 32.89 %
N2 27 17.76 %
N3 5 3.29 %
Missing data 2 1.32 %
Grade
G1 9 5.92 %
G2 80 52.63 %
G3 45 29.61 %
Missing data 18 11.84 %
HER2
Negative 107 70.39 %
Positive 21 13.82 %
Missing data 24 15.79 %
ER 0.00 %
Negative 63 41.45 %
Positive 86 56.58 %
Missing data 3 1.97 %
PgR
Negative 54 35.53 %
Positive 95 62.50 %
Missing data 3 1.97 %
Histological type
Ductal 104 68.42 %
Lobular 21 13.82 %
Other 14 9.21 %
Missing data 13 8.55 %
Molecular subtype
HR+, HER2− 83 54.61 %
HR+, HER2+ 9 5.92 %
HR−, HER2+ 14 9.21 %
TNBC 21 13.82 %
Missing data 25 16.45 %
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tumour cells and (iv) 3+/positive—strong reactivity in ≥10 %
of the tumour cells. Immunohistochemical staining was eval-
uated and scored independently by two observers (HMR and
RK). The agreement on staining intensity was >90 %. Where
there was disagreement, intensity was determined by consen-
sus. Final scores were dichotomized scores into (a) ‘negative’
for 0–1 and (b) ‘positive’ for 2–3.
Statistical analysis
All statistical analyses were performed by using the
STATISTICA software, version 10. Continuous variables
were compared by the Spearman’s rank order test. Disease-
free survival (DFS) was computed by using Kaplan-Meier
method and compared by using F Cox test. DFS was defined
as the time from surgery to an event (local or distant relapse,
second malignancy or death, whichever came first) or censor-
ing. Censoring was defined as lost to follow-up or survival
without relapse at the end of follow-up. Cox proportional haz-
ard regression analysis was used to identify the independent
predictors of DFS. The results were considered statistically
significant when p value was lower than 0.05.
Cell lines, antibodies and reagents
HB2 mammary epithelial cells were purchased from ECACC
(Sigma-Aldrich). Cells were grown in DMEM with 10 %
FBS, 5 μg/ml insulin, 5 μg/ml hydrocortisone and
penicillin/streptomycin (100 U/ml and 100 μg/ml, respective-
ly). Media and their supplements were from Sigma-Aldrich.
The following reagents were obtained from Santa Cruz
Biotechnology: rabbit anti-FGFR1 (sc-121), rabbit anti-
FGFR2 (sc-122), goat anti-RSK2 (sc-1430), mouse anti-
ubiquitin (sc-8017) and Protein G PLUS Agarose (sc-2002).
Mouse antibody against β-actin (A5316) was obtained from
Sigma-Aldrich. The remaining antibodies used in this study
were from Cell Signalling Technology: rabbit anti-FGFR-
Tyr653/654 (#3471) and rabbit anti-RSK2 (#5528). All
growth factors were obtained from PeproTech. Heparin sodi-
um salt, PD173074 inhibitor, ExtrAvidin-Peroxidase and re-
duced L-glutathione were purchased from Sigma-Aldrich.
FMK and BI-D1870 were from AxonMedchem. EZ-link
Sulfo-NHS-SS-biotin was obtained from Thermo Scientific.
Western blotting
Cells grown to 80–90 % confluence were lysed with Laemmli
b u f f e r ( 2 × c o n c e n t r a t e d ) c o n t a i n i n g 2 mM
phenylmethylsulfonyl fluoride (PMSF), 10 μg/ml aprotinin,
10 μg/ml leupeptin, 5 mM EGTA, 1 mM EDTA, 2 mM
Na4P2O7, 5 mMNaF and 5 mMNa3VO4. Samples with equal
amounts of protein per lane (∼20 μg) were loaded, resolved in
SDS polyacrylamide gel electrophoresis (SDS-PAGE) and
then transferred onto nitrocellulose membrane. The mem-
branes were incubated for 1 h in 5 % skimmed milk and
probed with specific antibodies overnight at 4 °C. Secondary
antibodies conjugated with HRP (Sigma-Aldrich) and
Western Lightning Plus-ECL (PerkinElmer) were used to vi-
sualize specific protein bands.
Immunoprecipitation
Cells were serum starved overnight, and, when required, me-
dia were supplemented with an appropriate inhibitor: FMK
(10 μM), BI-D1870 (1 μM) or PD173074 (100 nM). Cells
were then stimulatedwith FGF2 (10 ng/ml) + heparin sulphate
(50 ng/ml) or EGF (10 ng/ml) for indicated periods of time
before lysis in a suitable buffer. We independently applied
relatively harsh (1 % Triton X-100) or mild (0.8 % Brij96/
0.2% Triton X-100) detergent for cell lysis. Lysis buffers were
supplemented with the following inhibitors: 2 mM PMSF,
10 μg/ml aprotinin, 10 μg/ml leupeptin, 5 mM EGTA,
1 mM EDTA, 2 mM Na4P2O7, 5 mM NaF and 5 mM
Na3VO4. In the next step, cell lysates were incubated over-
night at 4 °C with constant rotation with anti-FGFR1 or anti-
FGFR2 antibodies coupled to Protein G Agarose (Santa Cruz
Biotechnology, sc-2002). Unbound proteins were removed by
extensive beads washing with lysis buffer; protein complexes
were eluted from the beads with Laemmli buffer. Samples
were resolved by SDS-PAGE and analysed by Western blot-
ting. To analyse FGFR2 ubiquitination, FGFR2 was
immunoprecipitated as described above; SDS-PAGE resolved
samples were probed with anti-ubiquitin antibodies.
Internalization assay
Serum-starved cells were placed on ice, washed twice in PBS
and labelled for 1 h with 500 μg/ml EZ-link Sulfo-NHS-SS-
biotin at 4 °C. Biotin excess was quenched by using 100 mM
glycine in PBS. Cells were then incubated with the prewarmed
serum-free DMEM containing FGF2 (10 ng/ml) + heparin
(50 ng/ml) at 37 °C for 60 min to induce internalization.
Plates were placed on ice and treated 2 × 20 min with ice-
cold stripping solution (500 mM glutathione (GSH), 75 mM
NaCl, 1 mM EDTA, 75 mM NaOH, supplemented with 1 %
FBS) to remove biotinylation from proteins that were not in-
ternalized from the plasma membrane. After washing with
PBS, cells were lysed in 1 % Triton X-100 buffer and
FGFR2 was immunoprecipitated as described above.
Samples were analysed by SDS-PAGE followed by Western
blotting with anti-Avidin-HRP and anti-FGFR2 antibodies.
Immunofluorescence staining
Cells seeded onto glass coverslips were serum-starved over-
night and stimulated with FGF2 for 20 min. Specimens were
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fixed with 2 % paraformaldehyde in PBS and permeabilized
with 0.1 % Triton X-100 in PBS for 1 min. After blocking
with 3 % BSA in PBS, cells were incubated with specific
primary antibodies: anti-RSK2 (1:75) and anti-FGFR2
(1:100) for 1 h. Cells were then stained with AffiniPure
DyLight 549-conjugated or DyLight 488-conjugated second-
ary antibodies (Jackson ImmunoResearch). Distribution of
analysed proteins was examined by using a fluorescence mi-
croscope ZEISS AxioVert 200.
Results
FGFR2 expression correlated with RSK2 at gene
and protein level in BCa
In normal gland, majority of cells displayed moderate/strong
expression of (i) cytoplasmic/membranous FGFR2 (Fig. 1a),
(ii) cytoplasmic/nuclear RSK2 (Fig. 1b) and (iii) cytoplasmic/
nuclear RSK-P (Fig. 1c). In BCa samples, immunoreactivity
for all proteins was highly heterogeneous with regards to both
cellular localization and level of expression. Examples of
levels of expression scored as 3+ (Fig. 1d–f) and 1+
(Fig. 1g–i) are presented on Fig. 1. FGFR2 expression showed
a positive, statistically significant association with RSK2
(p = 0.003) (Table 2 (a)). Similarly, at the mRNA level, there
was a significant correlation between expression of FGFR2
and RSK2 genes (p = 0.001) (Table 2 (b)). Moreover, values of
FGFR2/RSK2 correlation coefficients evaluated in the whole
group of patients were increased when analysis was restricted
to the TNBC subgroup only (p = 0.005 and p = 0.015 for gene
and protein expression, respectively).
FGFR2 and RSK2 status in relation to clinicopathological
data
Statistical analysis showed that FGFR2 expression in the
whole group of patients correlated only with positive ER sta-
tus (p = 0.0065). Expression of neither RSK2 nor RSK-P was
associated with any of clinicopathological variables
(Supplementary data, Table 1). At the mRNA level, no signif-
icant correlation with clinicopathological features was found
for FGFR2, while RSK2 was associated with grade (p = 0.02)
and PgR (p = 0.02) (average gene expression is presented in
Supplementary data Table 2).
Expression of FGFR2 and/or RSK-P is associated
with worse DFS
Patients with tumours positive for RSK-P had 2.134-fold
higher risk of recurrence when compared with the RSK-P-
negative group. When assessed in combination, expression
of either or both RSK-P and FGFR2 was associated with
4.89-fold risk of recurrence compared with the FGFR2/
RSK-P-negative patients (Table 3). High expression of RSK-
P correlated with worse disease-free survival (p = 0.025)
(Fig. 2a), whereas lack of both FGFR2 and RSK-P was pre-
dictive of better DFS (p = 0.01) (Fig. 2b). There was a trend
towards statistical significance of RSK-P as an independent
marker of recurrence (p = 0.065) (Table 3).
RSK2 and FGFR2 form transient complex in breast
cancer cells
Interactions between RSK2 and members of the FGFR family
have already been reported. For example, phosphorylated
Fig. 1 Expression of FGFR2,
RSK2 and RSK-P in BCa tissue
samples. a–c In normal gland, the
majority of cells displayed
moderate/strong expression of a
cytoplasmic/membranous of
FGFR2, b cytoplasmic/nuclear
RSK2 and c cytoplasmic/nuclear
RSK-P. Examples of
immunoreactivity for FGFR2,
RSK and RSK-P in BCa tissue
samples scored as 3+ (d–f) and 1+
(g–i). Corresponding tissue cores
under low magnification (insets).
Scale bar 500 μm
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RSK2 has been shown to bind to the C-terminal part of FGFR1
participate in regulation of its endocytosis and ubiquitination
[22]. In another study, RSK2 was found to be activated in the
FGF2/FGFR2-dependent signalling [19]. Herein, we found that
FGF2 treatment of HB2 mammary epithelial cell line (charac-
terized by high endogenous FGFR2 and RSK2 expression [19])
triggered co-localization of FGFR2 and RSK2 mostly at the
plasma membrane and perinuclear area (Supplementary data.
Fig 1). To verify a possible direct FGFR2-RSK2 interaction, we
performed co-immunoprecipitation experiments. HB2 cells
were serum-starved and treatedwith FGF2 for indicated periods
of time. As shown in Fig. 3a, RSK2 transiently (after 25–
30 min of exposure to FGF2) interacted with FGFR2.
FGFR2/RSK2 co-precipitation was also confirmed in triple-
nega t ive MDA-MB-231 breas t cancer ce l l l ine
(Supplementary data. Fig. 2). Analysed interaction took place
only when mild lysis conditions were applied (0.8 % Brij 96/
0.2 % Triton X-100). In the presence of a relatively harsh de-
tergent (1 % Triton X-100), the association of RSK2 with
FGFR2 was abolished (Fig. 3b). This suggests that RSK2 is a
member of larger protein complex interactingwith FGFR2 rath-
er than a direct FGFR2 partner. In contrary to the previously
published data [22], we did not notice any FGFR1-RSK2 inter-
actions (Fig. 3c).
To further study the nature of the FGFR2-RSK2 cross
talk, we evaluated its possible dependence on RSK2 and/
or FGFR2 activity. Cells were serum-starved in the pres-
ence of appropriate selective inhibitors and stimulated
with FGF2 or EGF (used as a control) for 30 min, where
indicated (Fig. 3d). Interaction between FGFR2 and
RSK2 was observed following stimulation with FGF2,
as shown before (Fig. 3a). Interestingly, we noticed little
increase in the amount of FGFR2/RSK2 complex follow-
ing EGF stimulation. Pretreatment with PD173074 (FGFR
Table 2 FGFR2 expression
correlates with RSK2 in BCa R Spearman p value Number
(A) Samples analysed by IHC for protein expression
Correlation/protein expression (IHC)
FGFR2 and RSK2 (whole cohort) 0.267 0.003 121
FGFR2 and RSK2 (TNBC) 0.6 0.015 16
FGFR2 and RSK-P (whole cohort) 0.112 0.6 119
FGFR2 and RSK-P (TNBC) 0.233 0.42 14
(B) Samples analysed by RT-qPCR for gene expression
Correlation/gene expression (RT-qPCR)
FGFR2 and RSK2 (whole cohort) 0.32 0.001 98
FGFR2 and RSK2 (TNBC) 0.552 0.005 24
Spearman rank correlation coefficients for FGFR2, RSK2 and RSK-P in the whole cohort and the TNBC
subgroup. Numerical values of correlation coefficients, p values and number of patients are presented in the
corresponding boxes
Table 3 Univariate and multivariate analysis of prognostic factors
Univariate analysis DFS Multivariate analysis DFS
Variable N Hazard ratio (95 % CI) p N Hazard ratio (95 % CI) p
Tumour size (T3–4 vs. T1–2) 151 4.745 (2.220–10.142) 0.00006 126 8.409 (3.315–21.334) 0.000007
Lymph nodes (positive vs. negative) 150 2.373 (1.091–5.162) 0.029 NS
ER (positive vs. negative) 149 0.523 (0.257–1.062) 0.073 NS
PgR (positive vs. negative) 149 0.367 (0.180–0.750) 0.006 NS
Histological type (lobular vs. ductal) 135 0.611 (0.184–2.026) 0.421 NS
Grade (G3 vs. G1–2) 132 1.469 (0.652–3.308) 0.353 NS
HER2 status (positive vs. negative) 128 1.348 (0.503–3.612) 0.553 NS
FGFR2 (positive vs. negative) 134 0.973 (0.406–2.3326) 0.950 NS
RSK2 (positive vs. negative) 124 0.699 (0.293–1.666) 0.419 NS
RSK-P (positive vs. negative) 127 2.134 (0.790–5.765) 0.135 126 2.577 (0.943–7.052) 0.065
FGFR2/RSK-P (rest vs. double-negative) 114 4.890 (0.651–36.731) 0.123 NS
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inhibitor) strongly abolished FGF2-triggered FGFR phos-
phorylation and FGFR2 association with RSK2. On the
other hand, application of BI-D1870, which inhibits
RSK-related activation of downstream substrates, leaving
the kinase itself phosphorylated, did not affect binding of
RSK2 to the FGFR2. In contrary, pretreatment of cells
with FMK, which binds in the C-terminal kinase domain
of RSK and inhibits RSK autophosphorylation, effectively
prevented formation of the RSK2-FGFR2 complex.
Efficiency of the inhibitors was tested by using antibodies
against RSK-P (Supplementary data. Fig. 3). These results
suggest that in mammary epithelial cells, RSK2 forms
transient indirect complex with FGFR2 upon FGF2-
initiated signalling and that this association depends on
activation of both FGFR2 and RSK2, rather than on
downstream activities of RSK2.
RSK activity regulates internalization of FGFR2
Several observations suggest that FGF receptors may undergo
endocytosis and regulated trafficking from the cell surface [22,
24, 25]. Here, an involvement of RSK in FGF2-triggered
FGFR2 internalization was studied (Fig. 4a). Cells were
surface-biotinylated at 0 °C and then stimulated with FGF2.
Biotinylated FGFR2 underwent internalization and, therefore,
was protected from glutathione stripping. Control samples
were surface-biotinylated and immediately washed with GSH
buffer to efficiently strip all biotin groups from cell surface
proteins (Fig. 4a). Immunoprecipitated FGFR2 was analysed
for the level of biotinylation. It has been observed that stimu-
lation with FGF2 promoted FGFR2 internalization. Cell pre-
treatment with specific RSK inhibitor (FMK) prevented FGF2-
mediated FGFR2 internalization suggesting that intracellular
Fig. 2 Kaplan-Meier curves
according to FGFR2 and RSK-P
protein status. a Disease-free
survival according to RSK-P level
(p = 0.025). b Disease-free
survival according to FGFR2/
RSK-P level (p = 0.01). Patients
were divided into the following
groups: FGFR2/RSK-P-double
negative and rest (positive for
either or both FGFR2 andRSK-P)
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trafficking of this receptor is regulated by RSK. We also
analysed potential role of RSK in FGFR2 turnover/degrada-
tion. RSK2 was transiently knock downed (Fig. 4b), and cells
were studied for the level of FGFR2 ubiquitination. We did not
find any differences in the amount of expressed FGFR2 or its
ubiquitination triggered by RSK2 silencing or inhibition of
RSK activity, which suggests that RSK2 takes part in internal-
ization of FGFR2 rather than its degradation.
Discussion
Expression levels of FGFR2 and RSK2 assessed independently
have been reported in several studies as negative prognostic
factors for patients with breast carcinoma [2, 3, 14]. As a
follow-on from our previous study demonstrating that FGFR2
activates RSK2 in BCa cells in vitro [19], herein we have
undertaken an evaluation of a potential clinical significance of
an interaction between FGFR2 and RSK2 in breast cancer.
We examined co-expression of FGFR2 and RSK2 in BCa
primary tumour samples. In the whole cohort, FGFR2 showed
a positive, statistically significant correlation with expression
of RSK2 at both protein (p = 0.003, Table 2 (a)) and mRNA
levels (p = 0.001, Table 2 (b)). Interestingly, statistical repre-
sentation of FGFR2/RSK2 co-expression (correlations coeffi-
cients) reached the highest value in the TNBC subgroup
(Table 2 (b)), indicating that FGFR2/RSK2 interdependence
might be associated with aggressive BCa subtype. Indeed,
several studies have already suggested that FGFR2 and
RSK2 play an important role in TNBC. siRNA-based screen-
ing aimed to identify therapeutic targets for individual breast
cancer subtypes recognized RSK2 as one of three genes with
potential clinical significance for the TNBC subgroup [26].
Silencing of RSK2 in triple-negative BCa cells delayed tu-
mour initiation in mice and strongly affected cell survival
in vitro [14]. On the other hand, expression of FGFR2 was
shown to correlate with decreased overall and disease-free
survival of BCa patients [3], and it is well documented that
FGFR2 gene amplification occurs most frequently in the
TNBC subgroup. Furthermore, small molecule inhibitors of
FGFR turned out to be a promising therapeutic strategy for
patients with TNBC, known to poorly respond to currently
available treatments [5].
Results of our study showed that RSK-P positivity was
associated with shorter DFS of BCa patients. Expression of
FGFR2 assessed alone had no prognostic value (data not
shown), but analysis of combined immunoreactivity for
FGFR2 and RSK-P revealed that lack of both was significant-
ly associated with better DFS (Fig. 2b). In addition, patients
with tumours positive for either or both FGFR2 and RSK-P
had 4.89-fold higher risk of recurrence when compared to the
FGFR2/RSK-P-negative subgroup. Lack of availability of
Fig. 3 FGFR2 transiently interacts with RSK2 in vitro. Serum-starved
mammary epithelial HB2 cells were treated with FGF2 for indicated
periods of time. Cell lysates were subjected to co-immunoprecipitation
with FGFR2 antibodies in amild (0.8 % Brij96/0.2 % Triton X-100) or b
harsh (1 % Triton X-100) lysis conditions. c Co-immunoprecipitation of
FGFR1 and RSK2 by using mild detergent for cell lysis. d FGFR2/RSK2
interaction depends on both FGFR and RSK activities. Cells were
pretreated with appropriate FGFR or RSK inhibitors in serum-free
media and stimulated with FGF2. FGFR2/RSK2 complexes were
immunoprecipitated in mild lysis conditions
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specific antibodies recognizing activated form of FGFR2 or
activated RSK2 imposes certain limitations on functional in-
terpretation of these findings. However, in light of our previ-
ous report demonstrating an involvement of RSK2 in FGFR2
downstream signalling [19], an assumption that an interaction
between FGFR2 and RSK2 promotes BCa progression seems
to be fully justified. In contrast to the study by Sun et al. where
cytoplasmic expression of FGFR2 was reported to correlate
with tumour size [3], our results demonstrated an association
of FGFR2 only with ER (p = 0.0065) (Supplementary data.
Table 1). Discrepancies between these findings may be due to
differences in analysed cohorts. While our group comprised
various histological BCa subtypes, the study by Sun et al. was
restricted only to patients with invasive ductal carcinoma
grade 2 (N = 125). Moreover, unlike Sun’s study, where nu-
clear and cytoplasmic expressions of FGFR2 were separately
evaluated, differences in FGFR2 subcellular localization were
not taken into account in our analysis.
Associations between members of FGFR and RSK families
have been previously reported by us and others [19–22]. The
present study undertakes an investigation of an FGFR2/RSK2
interdependence in HB2 mammary epithelial cell line character-
ized by high endogenous FGFR2 and RSK2 expression [19].
Co-immunoprecipitation in serum-starved cells treated with
FGF2 revealed a transient interaction between FGFR2 and
RSK2 kinase (Fig. 3a). Formation of this complex seemed to
be dependent on lysis conditions and occurred only in the pres-
ence of a mild detergent (0.8 % Brij 96/0.2 % Triton X-100),
which suggests that RSK2 might be a member of a larger
FGFR2-interacting protein complex rather than a direct FGFR2
partner. In the control experiment, in contrary to observations
reported by Nadratowska-Wesolowska [22], we observed no
interaction between FGFR1 and RSK2 (Fig. 3c). This could be
due to phenotypic differences between analysed cell lines, espe-
cially the FGFR expression profiles, and/or dissimilarities of
in vitro stimulation conditions with the FGFR ligands.
Having demonstrated that FGFR2 and RSK2 formed a
transient and indirect complex in HB2 cells, we went on to
establish whether their association was dependent on RSK2
and/or FGFR2 activity (Fig. 3d). Data presented in the Fig. 3d
indicate that pretreatment with PD173074-specific FGFR in-
hibitor or FMK, which binds in the C-terminal kinase domain
Fig. 4 RSK regulates
internalization but not turnover of
FGFR2. a Serum-starved HB2
mammary epithelial cells treated
with FMK and/or FGF2 were
surface-biotinylated and lysed.
FGFR2 was immunoprecipitated
and probed for ExtrAvidin. b
Analysis of FGFR2
ubiquitination in response to
RSK2 silencing
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of RSK and inhibits RSK autophosphorylation, nearly
completely abolished formation of the FGFR2/RSK2 com-
plex. On the other hand, application of BI-D1870, which
binds to N-terminal kinase domain (NTKD) of RSK and in-
hibits RSK activity towards downstream substrates, while
leaving the kinase itself phosphorylated, did not have any
impact on FGFR2/RSK2 association. These data are in agree-
ment with Nadratowska-Wesolowska et al., where BI-D1870
treatment had no effect on FGFR1-RSK2 complex formation
either (FMK was not studied) [22]. Therefore, we conclude
that formation of the FGFR2-RSK2 indirect complex upon
FGF2 stimulation depends on FGFR2 and RSK2 activation
rather than on RSK2 downstream signalling. Interestingly, in
control conditions, we found that EGF treatment resulted in a
slight increase in the amount of FGFR2-RSK2 complex (in
agreement with previous report [22]), which may be due to the
fact that EGF activates RSK2 through MAPK pathway, while
FGFR2 remains unphosphorylated [18].
Intracellular trafficking of cell surface receptors modulates
their signalling and cellular responses. Fibroblast growth fac-
tor receptors, like other receptor tyrosine kinases, in response
to ligand binding undergo internalization from cell surface and
controlled trafficking [22, 24, 25]. FGFR1 cleavage and inter-
nalization were proved to regulate pro-migratory gene expres-
sion. Inhibition of receptor trafficking abolished cell migration
and invasive phenotype [24]. RSK2 was shown to bind direct-
ly to the C-terminal tail of FGFR1 and direct receptor endo-
cytosis in human osteosarcoma cells [22]. We have found that
stimulation with FGF2 promoted FGFR2 internalization;
however pretreatment with specific RSK inhibitor (FMK) ef-
fectively prevented this effect. Subsequently, we examined a
potential role of RSK2 in FGFR2 turnover in HB2 cells with
stable RSK2 knockdown or treated with FMK. We found no
difference in the level of FGFR2 expression or its
ubiquitination resulting from RSK2 silencing or inhibition of
RSK activity (Fig. 4b). This suggests that RSK2 might play a
dual role for FGFR2 activities, i.e. it may mediate pro-
migratory effects of FGFR2 in BCa cells [19] as well as be
involved in regulation of FGFR2 intracellular trafficking.
To the best of our knowledge, this is the first study providing
information on clinical significance of FGFR2/RSK2 interde-
pendence in breast cancer patients. We demonstrated that
FGFR2, RSK2 and RSK-P were expressed in breast cancer
tissue and that patients with tumours devoid of RSK-P alone
or in combinationwith FGFR2 had longer disease-free survival.
Analysis of clinical material was supplemented by in vitro
mechanistic analyses showing that FGFR2 and RSK2 formed
an indirect complex in mammary epithelial cells. In addition,
RSK activity was found to exert a significant impact on FGF2-
triggered FGFR2 internalization. Taken together, our results
imply that FGFR2-RSK2 signalling pathway is associated with
BCa progression and evaluation of FGFR2/RSK-P expression
might be useful in disease prognostication.
BCa, breast cancer; DFS, disease-free survival; EGF, epi-
dermal growth factor; ER, oestrogen receptor; FGF2, fibroblast
growth factor 2; FGFR1, fibroblast growth factor receptor 1;
FGFR2, fibroblast growth factor receptor 2; FGFR3, fibroblast
growth factor receptor 3; GSH, glutathione; HER2, human
epidermal growth factor receptor 2; HR, hazard ratio; IGF-1,
insulin-like growth factor 1; IHC, immunohistochemistry; IP,
immunoprecipitation; PgR, progesterone receptor; RSK1, ri-
bosomal s6 kinase 1; RSK2, ribosomal s6 kinase 2; RSK-P,
phosphorylated ribosomal s6 kinases; RT-qPCR, reverse tran-
scription quantitative polymerase chain reaction; SDS-PAGE,
SDS polyacrylamide gel electrophoresis; SNP, single nucleo-
tide polymorphism; TICs, tumour-initiating cells; TMA, tu-
mour microarray; TNBC, triple-negative breast cancer.
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